Efficacy and safety of desvenlafaxine 25 and 50 Mg/Day in a randomized, placebo-controlled study of depressed outpatients

Journal of Psychiatric Practice

Volumn 19, Issue 1, 2013, Pages 5-14

  Iwata, Nakao ^a   Tourian, Karen A ^b   Hwang, Eunhee ^b   Mele, Linda ^b   Vialet, Cecile ^b  

^a FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^b PFIZER INC   (United States)

Author keywords

antidepressant agents; clinical trial; depression; desvenlafaxine; efficacy; safety

Indexed keywords

DESVENLAFAXINE; PLACEBO; PROLACTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HUMAN; HYPERTENSION; JAPAN; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; UNITED STATES; VITAL SIGN; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873847322     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000426323.59698.64     Document Type: Article

References (29)

1. Gelenberg AJ. The prevalence and impact of depression. J Clin Psychiatry 2010;71:e06.
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
3. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;21-7
4. Kawakami N, Shimizu H, Haratani T, et al. Lifetime and 6-month prevalence of DSM-III-R psychiatric disorders in an urban community in Japan. Psychiatry Res 2004;121: 293-301
5. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12: 3-21
6. Kawakami N. Epidemiology of depressive disorders in Japan and the world. Nihon Rinsho 2007;65:1578-84
7. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: Results from the World Health Surveys. Lancet 2007;370:851-8
8. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, 2011 (available at http://labeling.pfizer.com/ showlabeling.aspx ?id=497, accessed November 28, 2012).
9. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double- blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
10. DeMartinis NA, Yeung PP, Entsuah R, et al. A doubleblind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
11. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22: 338-47
12. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
13. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
14. Tourian KA, Padmanabhan SK, Groark J, et al. Desven - lafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31:1405-23
15. Feiger AD, Tourian KA, Rosas GR, et al. A placebo-controlled study evaluating the efficacy and safety of flexibledose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009;14:41-50
16. Rickels K, Montgomery SA, Tourian KA, et al. Desven - lafaxine for the prevention of relapse in major depressive disorder: Results of a randomized trial. J Clin Psycho - pharmacol 2010;30:18-24
17. Liebowitz MR, Tourian KA, Hwang E, et al. A randomized, double-blind, placebo-controlled study of desvenlafaxine 10 and 50 mg/d efficacy and safety in depressed outpatients. Poster presented at: Annual Meeting of the American Psychiatric Association; May 14-19, 2011; Honolulu, HI
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96
20. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976;217-22
21. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-9
22. Bech P. Quality of life in the psychiatric patient. London: Mosby-Wolfe 1998 (information on the scale available at http://www.who-5.org, accessed November 28, 2012).
23. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association; 2000:113-5
24. Cohen J. A power primer. Psychol Bull 1992;112:155-9
25. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: A systematic review and meta-analysis. Drug Saf 2008;31:851-65
26. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
27. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2008 (available at labeling.pfizer.com /showlabeling.aspx?id=100, accessed November 28, 2012).
28. Gentil V, Kerr-Correa F, Moreno R, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000;14:61-6
29. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64